IN8bio Publishes Review on γδ T Cell Therapies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Source: Newsfilter
- Research Advances: IN8bio's review published in Nature Communications highlights recent advancements in γδ T cell engineering and combination therapies, showcasing their potential in tumor immunotherapy, particularly for difficult-to-treat solid tumors.
- Increasing Clinical Trials: The number of actively recruiting γδ T cell clinical trials is rising globally, reflecting growing academic and industry interest in this platform, which may drive innovation in future treatment options.
- Unique Biological Properties: γδ T cells can recognize stress-associated signals, overcoming limitations of traditional immunotherapies, particularly in addressing immune escape mechanisms, demonstrating their crucial role in tumor immune surveillance.
- Product Pipeline: IN8bio's pipeline includes candidates like INB-600, INB-100, and INB-200/400, aimed at addressing unmet medical needs, especially in oncology and autoimmune diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INAB
Wall Street analysts forecast INAB stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.450
Low
36.00
Averages
92.00
High
180.00
Current: 1.450
Low
36.00
Averages
92.00
High
180.00
No data
About INAB
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IN8bio Publishes Review on γδ T Cell Therapies
- Research Advances: IN8bio's review published in Nature Communications highlights recent advancements in γδ T cell engineering and combination therapies, showcasing their potential in tumor immunotherapy, particularly for difficult-to-treat solid tumors.
- Increasing Clinical Trials: The number of actively recruiting γδ T cell clinical trials is rising globally, reflecting growing academic and industry interest in this platform, which may drive innovation in future treatment options.
- Unique Biological Properties: γδ T cells can recognize stress-associated signals, overcoming limitations of traditional immunotherapies, particularly in addressing immune escape mechanisms, demonstrating their crucial role in tumor immune surveillance.
- Product Pipeline: IN8bio's pipeline includes candidates like INB-600, INB-100, and INB-200/400, aimed at addressing unmet medical needs, especially in oncology and autoimmune diseases.
See More
IN8bio Updates Clinical Data on DeltEx DRI Therapy
- Significant Survival Extension: IN8bio's DeltEx DRI therapy achieved a median progression-free survival (mPFS) of 13.0 months in patients receiving up to six repeat doses, nearly doubling the 6.6 months seen in standard-of-care (SOC) patients, indicating the therapy's potential to improve outcomes for newly diagnosed glioblastoma patients.
- Improved Overall Survival: The median overall survival (mOS) for patients treated with DeltEx DRI exceeds 19.5 months, representing a 48% increase compared to the 13.2 months mOS for SOC patients, with approximately 43% of DeltEx DRI patients alive at 24 months, significantly higher than the 20% survival rate for SOC patients.
- Good Safety Profile: Clinical studies demonstrated that DeltEx DRI treatment was generally well tolerated among patients, with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity events reported, indicating a favorable safety profile for clinical application.
- Immune Reconstitution Mechanism: The research indicated that DeltEx DRI treatment drove a shift in the tumor microenvironment, enhancing T cell infiltration and significantly reducing immunosuppressive granulocytes, suggesting that the therapy not only targets tumor cells directly but may also sustain immune competency during chemotherapy.
See More
IN8bio Reports Q1 Loss but Promising Data Ahead
- Earnings Report: IN8bio's Q1 GAAP EPS stands at -$0.26, reflecting a loss; however, the company's advancements in R&D indicate potential growth opportunities moving forward.
- Platform Development: The firm is advancing its next-generation γδ T cell engager platform, with initial animal data expected in 2026, laying the groundwork for future clinical applications.
- Clinical Data Highlights: IN8bio's reported glioblastoma (GBM) data shows approximately a 97% improvement in progression-free survival compared to standard care, indicating significant efficacy of its treatment approach.
- Future Outlook: Updated median overall survival (mOS) data is set to be presented at ASCO 2026, which is expected to further bolster investor confidence in the company's therapeutic potential.
See More
IN8bio Advances γδ T Cell Engager Platform with Promising Data
- Clinical Data Breakthrough: IN8bio's updated clinical trial data from January 2026 reveals that the median progression-free survival (mPFS) for repeat-dose patients is 13.0 months, representing a 97% improvement over the standard-of-care group's 6.6 months, indicating significant therapeutic efficacy and potential for better patient outcomes.
- Survival Improvement: The median overall survival (mOS) for repeat-dose patients currently stands at 17.2 months, surpassing the 13.2 months for the standard treatment group, with several patients remaining progression-free beyond two years, highlighting the long-term efficacy and potential of this therapy.
- R&D Day Event: IN8bio is set to host its R&D Day on May 21, 2026, in New York City, where it will share the latest advancements of its γδ T cell platform, attracting attention from investors and industry experts regarding its innovations in oncology and autoimmune diseases.
- Financial Position Improvement: As of March 31, 2026, IN8bio's cash position was $21.9 million, a significant increase from $11.9 million in the same period last year, reflecting the company's positive progress in financial management and R&D investments.
See More
IN8bio Reports FY Loss and Launches $40.2M Private Placement
- Earnings Miss: IN8bio's FY GAAP EPS of -$4.44 falls short by $1.22, indicating significant challenges in profitability that could undermine investor confidence and negatively impact stock performance.
- Private Placement Announcement: The company has initiated a private placement of up to $40.2 million at-the-market, aimed at bolstering liquidity to support future R&D and operations, reflecting the urgency for funding amid current financial pressures.
- Quant Rating Insights: Seeking Alpha's Quant Rating on IN8bio suggests a cautious market outlook regarding its future performance, which may influence investor decisions and demand for its stock.
- Historical Financial Trends: Historical earnings data for IN8bio reveals a persistent trend of losses, prompting investors to closely monitor the company's potential for long-term profitability improvement to assess future investment risks and returns.
See More
IN8bio Appoints New President and COO
- Executive Appointment: IN8bio has promoted Kate Rochlin to president and chief operating officer, effective immediately, recognizing her leadership since serving as COO since December 2021, which reflects the company's confidence in her capabilities.
- Funding Initiative: IN8bio plans to raise up to $40.2 million through an at-the-market private placement, aimed at strengthening its capital structure and providing financial support for future R&D and operations, thereby driving growth in the biopharmaceutical sector.
- Historical Performance Review: Historical financial data for IN8bio indicates robust revenue growth over the past fiscal year, showcasing the company's competitiveness and the sustained demand in the biopharmaceutical market.
- Quant Rating Insight: Seeking Alpha's Quant Rating on IN8bio reveals a positive market outlook for its future performance, potentially attracting more investor interest and enhancing the company's stock price performance.
See More
IN8bio Publishes Review on γδ T Cell Therapies
- Research Advances: IN8bio's review published in Nature Communications highlights recent advancements in γδ T cell engineering and combination therapies, showcasing their potential in tumor immunotherapy, particularly for difficult-to-treat solid tumors.
- Increasing Clinical Trials: The number of actively recruiting γδ T cell clinical trials is rising globally, reflecting growing academic and industry interest in this platform, which may drive innovation in future treatment options.
- Unique Biological Properties: γδ T cells can recognize stress-associated signals, overcoming limitations of traditional immunotherapies, particularly in addressing immune escape mechanisms, demonstrating their crucial role in tumor immune surveillance.
- Product Pipeline: IN8bio's pipeline includes candidates like INB-600, INB-100, and INB-200/400, aimed at addressing unmet medical needs, especially in oncology and autoimmune diseases.
See More
IN8bio Updates Clinical Data on DeltEx DRI Therapy
- Significant Survival Extension: IN8bio's DeltEx DRI therapy achieved a median progression-free survival (mPFS) of 13.0 months in patients receiving up to six repeat doses, nearly doubling the 6.6 months seen in standard-of-care (SOC) patients, indicating the therapy's potential to improve outcomes for newly diagnosed glioblastoma patients.
- Improved Overall Survival: The median overall survival (mOS) for patients treated with DeltEx DRI exceeds 19.5 months, representing a 48% increase compared to the 13.2 months mOS for SOC patients, with approximately 43% of DeltEx DRI patients alive at 24 months, significantly higher than the 20% survival rate for SOC patients.
- Good Safety Profile: Clinical studies demonstrated that DeltEx DRI treatment was generally well tolerated among patients, with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity events reported, indicating a favorable safety profile for clinical application.
- Immune Reconstitution Mechanism: The research indicated that DeltEx DRI treatment drove a shift in the tumor microenvironment, enhancing T cell infiltration and significantly reducing immunosuppressive granulocytes, suggesting that the therapy not only targets tumor cells directly but may also sustain immune competency during chemotherapy.
See More
IN8bio Reports Q1 Loss but Promising Data Ahead
- Earnings Report: IN8bio's Q1 GAAP EPS stands at -$0.26, reflecting a loss; however, the company's advancements in R&D indicate potential growth opportunities moving forward.
- Platform Development: The firm is advancing its next-generation γδ T cell engager platform, with initial animal data expected in 2026, laying the groundwork for future clinical applications.
- Clinical Data Highlights: IN8bio's reported glioblastoma (GBM) data shows approximately a 97% improvement in progression-free survival compared to standard care, indicating significant efficacy of its treatment approach.
- Future Outlook: Updated median overall survival (mOS) data is set to be presented at ASCO 2026, which is expected to further bolster investor confidence in the company's therapeutic potential.
See More
IN8bio Advances γδ T Cell Engager Platform with Promising Data
- Clinical Data Breakthrough: IN8bio's updated clinical trial data from January 2026 reveals that the median progression-free survival (mPFS) for repeat-dose patients is 13.0 months, representing a 97% improvement over the standard-of-care group's 6.6 months, indicating significant therapeutic efficacy and potential for better patient outcomes.
- Survival Improvement: The median overall survival (mOS) for repeat-dose patients currently stands at 17.2 months, surpassing the 13.2 months for the standard treatment group, with several patients remaining progression-free beyond two years, highlighting the long-term efficacy and potential of this therapy.
- R&D Day Event: IN8bio is set to host its R&D Day on May 21, 2026, in New York City, where it will share the latest advancements of its γδ T cell platform, attracting attention from investors and industry experts regarding its innovations in oncology and autoimmune diseases.
- Financial Position Improvement: As of March 31, 2026, IN8bio's cash position was $21.9 million, a significant increase from $11.9 million in the same period last year, reflecting the company's positive progress in financial management and R&D investments.
See More
IN8bio Reports FY Loss and Launches $40.2M Private Placement
- Earnings Miss: IN8bio's FY GAAP EPS of -$4.44 falls short by $1.22, indicating significant challenges in profitability that could undermine investor confidence and negatively impact stock performance.
- Private Placement Announcement: The company has initiated a private placement of up to $40.2 million at-the-market, aimed at bolstering liquidity to support future R&D and operations, reflecting the urgency for funding amid current financial pressures.
- Quant Rating Insights: Seeking Alpha's Quant Rating on IN8bio suggests a cautious market outlook regarding its future performance, which may influence investor decisions and demand for its stock.
- Historical Financial Trends: Historical earnings data for IN8bio reveals a persistent trend of losses, prompting investors to closely monitor the company's potential for long-term profitability improvement to assess future investment risks and returns.
See More
IN8bio Appoints New President and COO
- Executive Appointment: IN8bio has promoted Kate Rochlin to president and chief operating officer, effective immediately, recognizing her leadership since serving as COO since December 2021, which reflects the company's confidence in her capabilities.
- Funding Initiative: IN8bio plans to raise up to $40.2 million through an at-the-market private placement, aimed at strengthening its capital structure and providing financial support for future R&D and operations, thereby driving growth in the biopharmaceutical sector.
- Historical Performance Review: Historical financial data for IN8bio indicates robust revenue growth over the past fiscal year, showcasing the company's competitiveness and the sustained demand in the biopharmaceutical market.
- Quant Rating Insight: Seeking Alpha's Quant Rating on IN8bio reveals a positive market outlook for its future performance, potentially attracting more investor interest and enhancing the company's stock price performance.
See More
